Precigen, Inc. (PGEN)
|52 Week Range||1.0-2.9|
|1y Target Est||-|
|DCF Unlevered||PGEN DCF ->|
|DCF Levered||PGEN LDCF ->|
|Debt / Equity||71.06%||Buy|
Upgrades & Downgrades
Latest PGEN news
Founders at These 7 Companies Are Loading Up on Their Stock. Should You?
15 March 2023
The Executive Vice President of the Dish Network (NASDAQ: DISH ) is Jim DeFranco. He also happens to be a co-founder of the satellite TV provider.
Here's Why Precigen, Inc. (PGEN) Is a Great 'Buy the Bottom' Stock Now
14 March 2023
Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among...
5 Penny Stocks To Buy According To Analysts, Targets Up To 952%
7 March 2023
Penny stocks to buy according to analysts in 2023 The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 952% appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...
3 Penny Stocks The Insiders Are Buying
28 February 2023
Penny stocks come with many risks, but with those risks come the potential for great rewards. While there is no guarantee which penny stocks will deliver those rewards, following the insiders is 1 way...
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
16 February 2023
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.
3 Penny Stocks To Buy According To Insider Bets Up To $25 Million
6 February 2023
Penny stocks to buy according to insider trades this quarter. The post 3 Penny Stocks To Buy According To Insider Bets Up To $25 Million appeared first on Penny Stocks to Buy, Picks, News and Informat...
Precigen, Inc. (PGEN) Moves to Buy: Rationale Behind the Upgrade
27 January 2023
Precigen, Inc. (PGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference
19 December 2022
GERMANTOWN, Md. , Dec. 19, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...
Precigen, Inc. (PGEN) Q3 2022 Earnings Call Transcript
9 November 2022
Precigen, Inc. (NASDAQ:PGEN ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief E...
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >